Skip to content

Comparison of Effects of Statin Monotherapy and Statin / Ezetimibe Combination Therapy on Blood Glucose Metabolism in Type 2 Diabetic Patients with Hyperlipidemia

A single center, randomized, open-label, active comparator-controlled, parallel-group trial – 24 weeks explanatory pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004143
Enrollment
48
Registered
2019-07-16
Start date
2019-07-22
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Low-dose statin / ezetimibe rosuvastatin 5mg + ezetimibe 10mg (CRETEJETE) is similar to rosuvastatin 20mg (high-dose statin monotherapy) in LDL-cholesterol-lowering therapy, but does not increa

Sponsors

Kyung Hee University Hosipital at Gangdong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patients over 20 years old with type 2 diabetes 2) Those who are under the control of blood glucose control by lifestyle therapy or metformin alone. 3) Diagnosis of diabetes less than 10 years 4) When registering HbA1c = 8.0% 5) LDL cholesterol = 70 mg / dl 6) Those who have agreed with the written consent of the subject for participation in clinical trials

Exclusion criteria

Exclusion criteria: 1) Those who took a lipid lowering agent for more than a week within the last 3 months 2) Those who took a lipid lowering agent for more than one day in the past month 3) Within 3 months, major cardiovascular disease 4) Those who are taking medication for weight loss or who are scheduled 5) Those who are taking or are planning to take drugs that affect the metabolism of sugar, such as systemic steroids 6) Serum AST, ALT Upper Normal Limit more than 2 times 7) Serum creatinine> 1.5 mg / dl 8) Untreated hyperthyroidism, hypothyroidism 9) Triglyceride = 500 mg / dl 10) Malignant tumor under treatment 11) Pregnancy 12) Any person deemed unable to participate in research under the judgment of the researcher

Design outcomes

Primary

MeasureTime frame
Compare HbA1C changes

Secondary

MeasureTime frame
Comparison of fasting blood sugar change;Comparison of insulin change;Comparison of glucagon change;Comparison of HOMA-B change;Comparison of insulinogenic index change;Comparison of disposition index change;Comparison of HOMA-IR change;Comparison of Matsuda index change;Comparison of Stumvoll index change;Comparison of OGIS index change;Comparison of LDL cholesterol change;Comparison of Non-HDL cholesterol change;Comparison of ApoB change;Comparison of ApoB/Apo-A1 change;Comparison of High-sensitivity CRP change

Countries

Korea, Republic of

Contacts

Public Contactjunghwa lee

Kyung Hee University Hosipital at Gangdong

liungh@naver.com+82-2-440-7058

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026